Oppenheimer Reaffirms Confidence in Q32 Bio with $20 Target Oppenheimer has reiterated its Outperform rating for Q32 Bio, maintaining a $20 price target. This comes as the company shifts focus to its alopecia areata drug, bempikibart, following promising Phase 2a data. However, recent downgrades from other analysts reflect mixed sentiment on the stock's future potential.12